27LOW

PER

PERCHERON FPO [PER]
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also develops HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed Phase I clinical trial to targer v-domain immunoglobulin suppressor of T-cell activation and cancer cells. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Healthcare · ASX Small Cap
$0.0050 +0.0%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical47
Catalyst50
Sentiment50
Fundamental0
Momentum28
Risk Gate30
Get alerts when PER's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track PER — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Stochastic is deep in oversold territory — bounce conditions forming
  • Sitting near support — this level has held before and could attract buyers again
  • Drifting lower — down 9.1% over the last 5 days
  • Lagging the Small Ords index — relative strength of 0.70, underperforming its peers
  • Critical cash runway (1.8 quarters)
  • Low P/S ratio (3.2x)
  • Revenue in sharp decline (-42%)
  • EPS estimates revised downward (-10pts)
  • Near 52-week low (0% of range)
  • Micro-cap ($5-20M) - high risk
  • Rights issue announced - significant dilution
  • Dilution velocity warning (2 raises recently)
  • Sentiment is mixed — no strong consensus either way
  • Elevated dilution risk (2 recent capital raises)
  • Penny stock risk ($0.005)
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Piotroski F-Score weak (2/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 27% over the past year
  • Revenue declining at -42% — the top line is shrinking
  • The bigger volume days are the down days — volume-weighted momentum is negative (-0.45%/day)
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about PER
"What's driving PER's score?" "How does PER compare to peers?" "Key risks for PER?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Letter to Ineligible Shareholders
NONE Letter to Eligible Shareholders
NONE Non-renounceable Entitlement Offer Opens

Recent ASX Announcements

2026-03-23 Letter to Ineligible Shareholders
2026-03-23 Letter to Eligible Shareholders
2026-03-23 Non-renounceable Entitlement Offer Opens
2026-03-16 Letter to option holders
2026-03-16 Proposed issue of securities - PER

Key Metrics

$5.6M
Market Cap
903K
Avg Volume
1.9x
Vol Ratio
$0.01 — $0.01
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-84.6%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 70%
LLeader vs LaggardlaggardRS: -8
IInstitutional SponsorshipweakInst: 4%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #117 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:PER vs ATXPER vs PNVPER vs IMM
Scout Pro — Deeper Analysis for PER
Try Pro free for 30 days
Share this analysis

Track PER and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required